close

SCOLR Pharma, Inc., a pharmaceutical company, develops and formulates prescription, over-the-counter, and nutritional products. The company uses its controlled delivery technology platform and develops water soluble and insoluble drugs, as well as high and low dose drugs; analgesic, cardiovascular, diabetes, anti-nausea, and pulmonary products; and dietary supplement products, including combinations of glucosamine and chondroitin, calcium, and other dietary products. Its products include Ibuprofen, an analgesic used for the treatment of pain, fever, and inflammation; Pseudoephedrine, a decongestant that is used to relieve sinus pressure related to allergies and common cold; Raloxifene, an ingredient in Evista, which is used to prevent and treat osteoporosis; Ondansetron, a drug in Zofran that is used for anti-nausea and vomiting associated with chemotherapy and radiation treatments for cancer; Rivastigmine, an ingredient in Exelon used for the management of Alzheimer's disease; and Risperidone, an ingredient in Risperdal that is used for the management of schizophrenia and bipolar mania. The company has a strategic alliance with Perrigo Company for the manufacture, marketing, distribution, and sale of certain dietary supplements in the United States; research collaboration with BioCryst Pharmaceuticals to develop an oral formulation of peramivir, an antiviral compound for the treatment of seasonal and life threatening influenza; and a collaboration and license agreement with Dr. Reddy's Laboratories to pursue the development and commercialization of an oral prescription drug product. The company was formerly known as SCOLR, Inc. and changed its name to SCOLR Pharma, Inc. in July 2004. SCOLR Pharma, Inc. was founded in 1983 and is headquartered in Bothell, Washington.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	22.82
Volume	693316
Volume Avg	558090
52 Week High	27.28
52 Week Low	12.78
PE	31.23
PE (group average)	39
EPS Year	0.70
EPS change Q/Q	-30%
EPS change Q/Q Yr ago	250%
EPS change Q/Q next Q est	-30%
EPS change Y/Y	-78.85%
REV change Q/Q	-7.17%
REV change Q/Q Yr ago	51.58%
EPS next Q est	0.20
EPS next Y est	1.04
Divident Annual	0.00
Dividend Yield	0%